Amgen Inc.

Huyabio International, LLC

Corixa Corporation

Medarex Inc.

Cephalon, Inc.

Ribi Immunochem Research, Inc.

Huya Bioscience International, LLC

E. R. Squibb Sons, Inc.

Huya Biosciences International LLC

Chinese Academy of Sciences

Gary Elliott

Suzanne J Romano

Haichun Huang

Francis Hall Martin

Alison Witte

Mireille Gillings

Robert Goodenow

Brian C Varnum

Xueming Qian

Chris Vezina

David A Johnson

Shuqian Jing

Eugene Medlock

Richard Yeh

Patricia A Weber

Daniel Freeman

C Gregory Sowell

Qi Chao

Andrew A Welcher

David H Persing

Robert Radinsky

Scott Michael Silbiger

Rong Wang

Jory R Baldridge

Hayley Reece

Lorenzo Leoni

J Terry Ulrich

Richard Thomas Crane

Michael J Lacy

Hung Q Nquyen

Jay Mason

Curtis Tyree

Hung Q Nguyen

Frank Martin

Yiping Wang

Joseph Edward Gordon Benson

Jilin Sun

Kenneth H Jung

Waldemar Radziszewski

Sarah Collins

Pamela M Elliott

Donglu Bai

Scott Michael Sibiger

Mimi K Phillips

Greg Sowell

James R Paterniti, Jr

Lars Rogall

Dario Menia

Andreas Kyas

Ernst Freund

Oliver Schlorke

Jorg Lill

James R Paterniti

Oliver SCHLÖRKE

Provided herein are compositions and methods for administration of sulcardine to a subject in need thereof.

Sulcardine administration for treatment of acute atrial fibrillation

Sulcardine salts other than sulfuric acid salts of sulcardine, including crystalline sulcardine salts, are provided herein. Pharmaceutical compositions comprising such salts and methods of treating arrhythmias comprising administering effective amounts of such salts are also provided.

Sulcardine salts

Glove

Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.

Therapeutic human anti-IL-1R1 monoclonal antibody

The present application relates to methods of selecting EGFr binding agents. In certain embodiments, such EGFr binding agents bind to at least a portion of a panitumumab epitope on an EGFr. In certain embodiments, such EGFr binding agents do not bind to a panitumumab epitope on an EGFr.

Methods of selecting epidermal growth factor receptor (EGFr) binding agents

A composition comprised of an active agent that is 4-methoxy-N-(3,5-bis-(1-pyrrolidinyl)-4-hydroxy benzyl)benzene sulfonamide or a pharmaceutically acceptable salt thereof is intravenously administered to a subject, substantially evenly over a period of greater than about 15 minutes, to avoid disadvantageous hemodynamic effects, including systemic diastolic and systolic hypotension, to can occur with rapid intravenous or even short-term infusion administration of the active agent.

Slow infusion of sulcardine and its salts

Atrial fibrillation (AF) can be treated or prevented by administering to a subject who suffers from or is at risk of suffering from AF a composition comprised of an amount of an active agent, which is 4-methoxy-N-(3,5-bis(1-pyrrolidinyl)-4-hydroxy benzyl)benzene sulfonamide (sulcardine) or a pharmaceutically acceptable salt thereof, such that the Cmax value the active agent in the subject is in the range from about 1 &#x3bc;M to about 20 &#x3bc;M.

Treatment of atrial fibrillation

Methods and compositions for treating or ameliorating diseases and other conditions, such as infectious diseases, autoimmune diseases and allergies are provided. The methods employ mono- and disaccharide-based compounds for selectively stimulating immune responses in animals and plants.

Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds

Growing community of inventors

Thousand Oaks, CA, United States of America

Gary Elliott